Cost-Effectiveness of Blinatumomab Plus Chemotherapy vs Chemotherapy in Adults Newly Diagnosed with Philadelphia-Negative B-Cell Acute Lymphoblastic Leukemia in Italy
Gianni Ghetti, Luca Castello, Linet Awino Odonde, Serena De Fazio, Andrea Stella, Angela Bruno, Emanuele Marchionne, Massimiliano Bonifacio · 2026
Read Cost-Effectiveness of Blinatumomab Plus Chemotherapy vs Chemotherapy in Adults Newly Diagnosed with Philadelphia-Negative B-Cell Acute Lymphoblastic Leukemia in Italy by Gianni Ghetti, Luca Castello, Linet Awino Odonde, Serena De Fazio, Andrea Stella, Angela Bruno, Emanuele Marchionne, Massimiliano Bonifacio (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13271146.txt.
Description
Gianni Ghetti and seven colleagues present a 2026 health economics study asking whether an expensive leukemia drug earns its price in Italy. Blinatumomab, an immunotherapy, extends life when alternated with chemotherapy in adults newly diagnosed with a common ALL subtype, but Italy's health service had no local value estimate. The team modeled lifetime costs and outcomes from a large trial's data.
Patients on the combined regimen lived about five years longer and gained about four and a half quality-adjusted years. The extra cost ran to roughly one hundred sixty-five thousand euros per patient, mostly the drug's price. The cost per quality year, about thirty-six thousand euros, sits within Italy's usual acceptance range, and sensitivity checks kept it there. The authors endorse adoption.
Catalog record
| CREATOR | Gianni Ghetti, Luca Castello, Linet Awino Odonde, Serena De Fazio, Andrea Stella, Angela Bruno, Emanuele Marchionne, Massimiliano Bonifacio |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 40 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |